ABBVie today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis showing upadacitinib met the primary endpoint of Assessment in SpondyloArthritis International Society 40 response and the majority of ranked secondary endpoints at week 14. 1 Significantly more upadacitinib-treated patients achieved ASAS40 .
Targeting IL-23 Could Still Be Important for Axial SpA Treatment medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
AxSpA Evolution Tracked in First-Degree Relatives of Patients medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
- Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis[2-6]
- Approvals underscore AbbVie s longstanding commitment to deliver innovative medicines for people living with rheumatic diseases